Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.

Liu T, Shen JK, Li Z, Choy E, Hornicek FJ, Duan Z.

Cancer Lett. 2016 Apr 1;373(1):109-18. doi: 10.1016/j.canlet.2016.01.030. Epub 2016 Jan 21.

PMID:
26806808
2.

NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.

Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, Cote G, Harmon D, Mankin H, Gray NS, Hornicek FJ, Duan Z.

Br J Pharmacol. 2016 Feb;173(3):613-26. doi: 10.1111/bph.13395. Epub 2016 Jan 15.

PMID:
26603906
3.
4.

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells.

Zhang L, Lyer AK, Yang X, Kobayashi E, Guo Y, Mankin H, Hornicek FJ, Amiji MM, Duan Z.

Int J Nanomedicine. 2015 Apr 15;10:2913-24. doi: 10.2147/IJN.S79143. eCollection 2015.

5.

What do we know about canine osteosarcoma treatment? Review.

Szewczyk M, Lechowski R, Zabielska K.

Vet Res Commun. 2015 Mar;39(1):61-7. doi: 10.1007/s11259-014-9623-0. Epub 2014 Nov 26. Review.

6.

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.

Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ.

BMC Cancer. 2014 Sep 19;14:681. doi: 10.1186/1471-2407-14-681.

7.

Nanodrug delivery in reversing multidrug resistance in cancer cells.

Kapse-Mistry S, Govender T, Srivastava R, Yergeri M.

Front Pharmacol. 2014 Jul 10;5:159. doi: 10.3389/fphar.2014.00159. eCollection 2014. Review.

8.

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.

Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.

Br J Cancer. 2014 Jun 10;110(12):2896-904. doi: 10.1038/bjc.2014.254. Epub 2014 May 22.

9.

Molecular mechanisms of chemoresistance in osteosarcoma (Review).

He H, Ni J, Huang J.

Oncol Lett. 2014 May;7(5):1352-1362. Epub 2014 Mar 4.

10.

Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Callaghan R, Luk F, Bebawy M.

Drug Metab Dispos. 2014 Apr;42(4):623-31. doi: 10.1124/dmd.113.056176. Epub 2014 Feb 3. Review.

11.

In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles.

Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM.

J Control Release. 2013 Dec 28;172(3):699-706. doi: 10.1016/j.jconrel.2013.10.016. Epub 2013 Oct 22.

12.

Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy.

Singh S.

Bioimpacts. 2013;3(2):53-65. doi: 10.5681/bi.2013.007. Epub 2013 Jan 14.

13.

Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration.

Gu W, Wu C, Chen J, Xiao Y.

Int J Nanomedicine. 2013;8:2305-17. doi: 10.2147/IJN.S44393. Epub 2013 Jun 25. Review.

14.

Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.

Ganesh S, Iyer AK, Morrissey DV, Amiji MM.

Biomaterials. 2013 Apr;34(13):3489-502. doi: 10.1016/j.biomaterials.2013.01.077. Epub 2013 Feb 11.

15.

Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach.

Malmo J, Sandvig A, VĂ¥rum KM, Strand SP.

PLoS One. 2013;8(1):e54182. doi: 10.1371/journal.pone.0054182. Epub 2013 Jan 23.

16.

Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.

Kobayashi E, Iyer AK, Hornicek FJ, Amiji MM, Duan Z.

Clin Orthop Relat Res. 2013 Mar;471(3):915-25. doi: 10.1007/s11999-012-2610-2.

17.

MicroRNA Involvement in Osteosarcoma.

Kobayashi E, Hornicek FJ, Duan Z.

Sarcoma. 2012;2012:359739. doi: 10.1155/2012/359739. Epub 2012 Apr 3.

18.

Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms.

Su Y, Cheng X, Tan Y, Hu Y, Zhou Y, Liu J, Xu Y, Xie Y, Wang C, Gao Y, Wang J, Cheng T, Yang C, Xiong D, Miao H.

PLoS One. 2012;7(3):e32782. doi: 10.1371/journal.pone.0032782. Epub 2012 Mar 5.

19.

RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro.

Si H, Peng C, Li J, Wang X, Zhai L, Li X, Li J.

Int J Oncol. 2012 Apr;40(4):1291-7. doi: 10.3892/ijo.2011.1303. Epub 2011 Dec 15.

20.

'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics.

Abeylath SC, Amiji MM.

Bioorg Med Chem. 2011 Nov 1;19(21):6167-73. doi: 10.1016/j.bmc.2011.09.024. Epub 2011 Sep 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk